OTOTOXICITY EVALUATION OF ORAL CHELATORS IN BETA THALASSEMIA MAJOR PATIENTS
1Finike Devlet Hastanesi, KBB, Antalya, Türkiye Introduction: It was aimed to evaluate the hearing functions of thalassemia patients who received oral chelator therapy (deferiprone, deferasirox).Method and Material: Pure-tone audiometry was used to evaluate the sensorineural hearing status of transfusion-dependent thalassemia major patients, using oral chelator treatments who were followed up in a secondary stage state hospital.
Results: A total of 39 patients with beta-thalassemia major were included in the study. Twenty-three (59%) of the patients were male. The mean age of the patients was 28.66±8.91 years, the youngest patient was 7 years old, and the oldest patient was 43 years old. The mean age at diagnosis was 8.7±1.9 months. In none of the patients, no pathological value in favor of ototoxicity was detected in the audiometry data evaluated between 500 and 8000 Hertz.
Conclusion: In this study, no sensorineural hearing loss was found in transfusion-dependent thalassemia major patients using any of the oral chelation therapies.
Keywords : Sensorineural hearing loss, chelation therapy, thalassemia